SIRION Biotech returns to DG-GT gene therapy meeting

Important Information: The event, which was due to take place from 16th – 18th March 2020, has been postponed.

Martinsried, Germany: – Bavarian-based viral technology specialist SIRION Biotech GmbH will journey to the historic Castle Herrenhausen near Hannover for the annual meeting of the German Society for Gene Therapy (DG-GT e.v.).

SIRION has a well-established relationship with the event, which is sponsored by the Volkswagen Foundation.

Viral vector design

The SIRION team, led by Dr. Franziska Ruf and Dr. Galiya Sakaeva, will be looking to exchange knowledge with researchers in the fields of gene and cell therapies.

They will present SIRION’s particular expertise in viral vector design optimization and its innovative solutions for improvement of clinical trials that require lentiviral transduction enhancement developing adeno-associated viruses (AAVs) and viral vectors.

Gene therapy as clinical reality

Dr. Ruf commented: “DG-GT annual meeting is a great platform to exchange innovative ideas in the world of gene and cell therapies with very direct links to our core areas of research and innovation.”

“The 2020 Theme, ‘Making Gene Therapy a Clinical Reality’, perfectly encapsulates the SIRION mission,” she added.

About SIRION Biotech

Founded at Martinsried, near Munich, in 2007, SIRION Biotech has become Europe’s leading commercial supplier of viral vectors used for genetic research, clinical target validation, cell and gene therapy and vaccination studies. It is SIRION’s mission to change the paradigm for viral vector supplies, with their ability to develop and supply all major viral vector types (adenovirus, lentivirus, AAV) within a matter of weeks at the concentration titres and quantities needed for preclinical human and animal testing.

Its unique focus on improving transduction efficiencies and safety makes SIRION Biotech a valuable technology partner for gene and cell therapy trials. LentiBOOST^™ transduction reagent is actively used to improve, among others, hematopoietic cell transductions in clinical trials. NextGen AAV capsid evolution projects aim to improve tissue targeting and immune escape of capsids to usher in a new generation of therapeutics for international gene therapy companies. SIRION offerings include the transformational RNAiONE^™ knockdown validation platform along with a full range of virus related services, ranging from particle production to virus driven cell modelling.

SIRION Biotech International is a wholly-owned subsidiary of SIRION Biotech GmbH providing custom engineering and manufacturing services of viral vectors for the life sciences industry.

Learn more at: www.sirion-biotech.com

About DG-GT e.V 2020

The 27th Annual Meeting of the DG-GT e.V Deutchsce Gesellschaft für Gene Therapie (German Society for Gene Therapy) will be held March 16-18 at Castle Herrenhausen, historic seat of the ruling House of Hannover.

The three-day 2020 meeting, themed ‘’Making Gene Therapy a Clinical Reality’’, will discuss latest developments in areas such as delivery, optimizing cargo and microenvironment, iPSC- and stem cell-based cell therapies, novel approaches in cancer therapy and clinical translation of gene and cell therapies.

Up to 30 abstracts from internationally renowned scientists will be selected for presentation and there will also be a poster session featuring five-minute presentations. The half-day education session before the conference opens will present updates on current state of the art technologies.

More information at: https://dg-gt.de/congress/dg-gt-hannover-2020.aspx